mTOR kinase inhibition triggers feedback-dependent biphasic AKT reactivation, informing resistance.
| Evidence tier | D Mechanistic / in vitro / review |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Cancer cells |
| Journal | Cancer discovery |
| Year | 2011 |
| Peer reviewed | Yes |
| Source | DOI 10.1158/2159-8290.CD-11-0085 · PMID 22140653 · Free full text (PMC3227125) |
mTOR kinase inhibitors block mTORC1 and mTORC2 and thus do not cause the mTORC2 activation of AKT observed with rapamycin. We now show, however, that these drugs have a biphasic effect on AKT. Inhibition of mTORC2 leads to AKT serine 473 (S473) dephosphorylation and a rapid but transient inhibition of AKT T308 phosphorylation and AKT signaling. However, inhibition of mTOR kinase also relieves feedback inhibition of receptor tyrosine kinases (RTK), leading to subsequent phosphoinositide 3-kinase activation and rephosphorylation of AKT T308 sufficient to reactivate AKT activity and signaling. Thus, catalytic inhibition of mTOR kinase leads to a new steady state characterized by profound suppression of mTORC1 and accumulation of activated AKT phosphorylated on T308, but not S473. Combined inhibition of mTOR kinase and the induced RTKs fully abolishes AKT signaling and results in substantial cell death and tumor regression in vivo. These findings reveal the adaptive capabilities of oncogenic signaling networks and the limitations of monotherapy for inhibiting feedback-regulated pathways.
| Intervention | ATP-competitive mTOR kinase inhibitors |
| Target | mTORC1/2 / AKT / RTK |
| Model | Cancer cells |
| Effect | mTOR kinase inhibition causes feedback-dependent biphasic AKT regulation (transient inhibition then RTK-driven rebound) |